Literature DB >> 16951230

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

Andrew J Holloway1, Dileepa S Diyagama, Ken Opeskin, Jenette Creaney, Bruce W S Robinson, Richard A Lake, David D L Bowtell.   

Abstract

PURPOSE: Patients with malignant mesothelioma or adenocarcinoma of the lung often present with respiratory complications associated with a malignant pleural effusion. Distinguishing between these malignancies is frequently problematic, as many of the clinical, cytologic, and histologic features of the diseases overlap. Following cytologic analysis of pleural effusions, subsequent confirmatory tissue biopsies involve increased patient morbidity and expense. We have therefore designed a gene expression-based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself. EXPERIMENTAL
DESIGN: We have used microarray data for 190 lung adenocarcinomas and 33 malignant mesotheliomas to identify genes differentially expressed between the two diseases. Genes expressed in normal mesothelial cells were removed, allowing the development of a PCR-based test to measure the expression of genes that discriminate between mesothelioma and lung adenocarcinoma from cytology specimens.
RESULTS: Applying an real-time PCR-based assay involving 17 genes to 13 independent samples from biopsy-proven malignant mesothelioma and lung adenocarcinomas resulted in the correct identification of all samples.
CONCLUSIONS: We have developed a test that is able to distinguish between lung adenocarcinoma and mesothelioma in cells collected from pleural effusions.

Entities:  

Mesh:

Year:  2006        PMID: 16951230     DOI: 10.1158/1078-0432.CCR-06-1027

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Authors:  Hila Benjamin; Danit Lebanony; Shai Rosenwald; Lahav Cohen; Hadas Gibori; Naama Barabash; Karin Ashkenazi; Eran Goren; Eti Meiri; Sara Morgenstern; Marina Perelman; Iris Barshack; Yaron Goren; Tina Bocker Edmonston; Ayelet Chajut; Ranit Aharonov; Zvi Bentwich; Nitzan Rosenfeld; Dalia Cohen
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

2.  Identification of novel markers for the diagnosis of malignant pleural mesothelioma.

Authors:  Fabien Gueugnon; Sabrina Leclercq; Christophe Blanquart; Christine Sagan; Laurent Cellerin; Martine Padieu; Christian Perigaud; Arnaud Scherpereel; Marc Gregoire
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.

Authors:  Brock C Christensen; Carmen J Marsit; E Andres Houseman; John J Godleski; Jennifer L Longacker; Shichun Zheng; Ru-Fang Yeh; Margaret R Wrensch; Joseph L Wiemels; Margaret R Karagas; Raphael Bueno; David J Sugarbaker; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

Review 4.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Authors:  Jenette Creaney; Ian M Dick; Justine S Leon; Bruce W S Robinson
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

6.  Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma.

Authors:  Chuan Bian Lim; Cecilia M Prêle; Hui Min Cheah; Yuen Yee Cheng; Sonja Klebe; Glen Reid; D Neil Watkins; Svetlana Baltic; Philip J Thompson; Steven E Mutsaers
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

Review 7.  Markers for the non-invasive diagnosis of mesothelioma: a systematic review.

Authors:  S van der Bij; E Schaake; H Koffijberg; J A Burgers; B A J M de Mol; K G M Moons
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

8.  A gene expression ratio-based diagnostic test for bladder cancer.

Authors:  Lingsheng Dong; Andrew J Bard; William G Richards; Matthew D Nitz; Dan Theodorescu; Raphael Bueno; Gavin J Gordon
Journal:  Adv Appl Bioinform Chem       Date:  2009-01-12

9.  Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.

Authors:  Gökçen Ömeroğlu Şimşek; İsmail Ağababaoğlu; Duygu Dursun; Selver Özekinci; Pınar Erçetin; Hülya Ellidokuz; Safiye Aktaş; Duygu Gürel; İlhan Öztop; Atila Akkoçlu
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

10.  Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.

Authors:  J Creaney; A Segal; G Sterrett; M A Platten; E Baker; A R Murch; A K Nowak; B W S Robinson; M J Millward
Journal:  Br J Cancer       Date:  2008-04-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.